Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01694602 · ClinicalTrials.gov registry record
Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II
A clinical trial, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- 8
- Enrollment target
NCT01694602: Completed study, sponsored by The University of Texas Medical Branch, Galveston.
NCT01694602 is a clinical trial that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01694602 has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
The overall aim of this research is to develop a non-invasive approach to evaluate the production of 3-methylhistidine (3MH)in cancer patients, as a potential means of determining which patients are at high risk for future development of cancer induced skeletal muscle atrophy. Rationale: The approach is based on the hypothesis that after an oral dose of deuterated 3-methylhistidine (D-3MH), the slope of the terminal portion of the decay curve (\> 12 hours post-dosing) for the tracer/tracee (D-3MH/3MH) in the free 3MH pool is proportional to the rate constant for myofibrillar protein degradation and can be determined from spot urine samples.
Interventions
- BIOLOGICAL (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-06 |
What the finished NCT01694602 record still lists
NCT01694602 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH) is the first listed.
NCT01694602 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01694602 about?
NCT01694602 is a clinical study titled "Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II". The overall aim of this research is to develop a non-invasive approach to evaluate the production of 3-methylhistidine (3MH)in cancer patients, as a potential means of determining which patients are at high risk for future development of cancer induced skeletal muscle atrophy. Rationale: The approa...
What is the current status of trial NCT01694602?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2012-11. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01694602?
The interventions under investigation include: (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01694602?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia